Fig. 1: Time to deterioration of PROs for Azacitidine based patients. | Blood Cancer Journal

Fig. 1: Time to deterioration of PROs for Azacitidine based patients.

From: Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia

Fig. 1

Time to deterioration in EORTC GHS/QoL (A), PROMIS Fatigue (B), EORTC PF (C), and Health Status (EQ-5D-5L) VAS (D), VEN + AZA versus PBO + AZA. Time to deterioration thresholds for EORTC-QLQ-C30, EQ-5D-5L VAS, and PROMIS Fatigue are ≥10, 7, or 5 points, respectively. Time to deterioration analyses were conducted for all patients in the full dataset with available data on ≥1 PRO measures from baseline to the given assessment (N = VEN + AZA 262, 264, 262, and 260, and PBO + AZA 130, 132, 130, and 130 for EORTC GHS/QoL, fatigue, PF, and health status VAS, respectively). AZA azacitidine, CI confidence interval, EORTC QLQ-C30 European Organization for Research and Treatment of Cancer quality of life questionnaire, EQ-5D-5L EuroQoL 5-Dimension 5-Level, GHS global health status, NE not estimable, PBO placebo, PF physical functioning, PROMIS Patient-Reported Outcomes Measurement Information System, QoL quality of life, VAS visual analog scale, VEN venetoclax.

Back to article page